Literature DB >> 8505636

Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.

H Shinotoh1, O Inoue, K Hirayama, A Aotsuka, M Asahina, T Suhara, T Yamazaki, Y Tateno.   

Abstract

Striatal dopamine D1 receptors were investigated in 11 patients with Parkinson's disease (PD), five patients with striatonigral degeneration (SND) and six age-matched controls by positron emission tomography and carbon-11 labelled SCH23390. The SND patients showed mean 12%, 21%, and 31% declines in the ratios of radioactivity in the caudate, anterior putamen, and posterior putamen compared with that in the occipital cortex. These ratios were not significantly altered in the PD patients. The results may explain the different therapeutic responses to levadopa between SND and PD patients, and this technique might prove useful for their differentiation.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8505636      PMCID： PMC1015002          DOI： 10.1136/jnnp.56.5.467

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  29 in total

1.  Computer-controlled large scale production of high specific activity [11C]RO 15-1788 for PET studies of benzodiazepine receptors.

Authors:  K Suzuki; O Inoue; K Hashimoto; T Yamasaki; M Kuchiki; K Tamate
Journal:  Int J Appl Radiat Isot       Date:  1985-12

2.  D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects.

Authors:  J R Walters; D A Bergstrom; J H Carlson; T N Chase; A R Braun
Journal:  Science       Date:  1987-05-08       Impact factor: 47.728

3.  Magnetic resonance imaging of the midbrain in Parkinson's disease.

Authors:  J R Duguid; R De La Paz; J DeGroot
Journal:  Ann Neurol       Date:  1986-12       Impact factor: 10.422

4.  [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease.

Authors:  C Pimoule; H Schoemaker; G P Reynolds; S Z Langer
Journal:  Eur J Pharmacol       Date:  1985-08-15       Impact factor: 4.432

5.  Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects.

Authors:  R Raisman; R Cash; M Ruberg; F Javoy-Agid; Y Agid
Journal:  Eur J Pharmacol       Date:  1985-07-31       Impact factor: 4.432

6.  Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum.

Authors:  J C Stoof; J W Kebabian
Journal:  Nature       Date:  1981-11-26       Impact factor: 49.962

7.  Statistics in practice. Comparing the means of several groups.

Authors:  K Godfrey
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

8.  Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease.

Authors:  R Cash; R Raisman; A Ploska; Y Agid
Journal:  J Neurochem       Date:  1987-10       Impact factor: 5.372

9.  Dopamine D-1 receptors in the parkinsonian brain.

Authors:  J O Rinne; J K Rinne; K Laakso; P Lönnberg; U K Rinne
Journal:  Brain Res       Date:  1985-12-16       Impact factor: 3.252

10.  Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease.

Authors:  M Quik; E G Spokes; A V Mackay; R Bannister
Journal:  J Neurol Sci       Date:  1979-11       Impact factor: 3.181
View more
  15 in total

Review 1.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 3.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

4.  Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.

Authors:  Jean-Christophe Corvol; Marie-Paule Muriel; Emmanuel Valjent; Jean Féger; Naïma Hanoun; Jean-Antoine Girault; Etienne C Hirsch; Denis Hervé
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

5.  Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.

Authors:  J B Schulz; T Klockgether; D Petersen; M Jauch; W Müller-Schauenburg; S Spieker; K Voigt; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

6.  Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.

Authors:  J Sun; N J Cairns; J S Perlmutter; R H Mach; J Xu
Journal:  Neuroscience       Date:  2013-06-01       Impact factor: 3.590

7.  In vivo imaging of disturbed pre- and post-synaptic dopaminergic signaling via arachidonic acid in a rat model of Parkinson's disease.

Authors:  Abesh Kumar Bhattacharjee; Lindsey M Meister; Lisa Chang; Richard P Bazinet; Laura White; Stanley I Rapoport
Journal:  Neuroimage       Date:  2007-06-27       Impact factor: 6.556

8.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

Review 9.  Dopamine receptor mapping with PET imaging in Parkinson's disease.

Authors:  Flavia Niccolini; Paul Su; Marios Politis
Journal:  J Neurol       Date:  2014-03-15       Impact factor: 4.849

10.  Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease.

Authors:  Lior Greenbaum; Mordechai Lorberboym; Eldad Melamed; Amihai Rigbi; Yael Barhum; Yoav Kohn; Alexander Khlebtovsky; Bernard Lerer; Ruth Djaldetti
Journal:  Front Neurosci       Date:  2013-04-15       Impact factor: 4.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.